Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. AZD8895 have strong neutralizing activity against SARS-CoV-2 and variants of concern with antigenic substitutions in the RBD. AZD8895 binds to the receptor-binding ridge of RBD. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 |
Epitope | RBD receptor binding domain |
Isotype | IgG1 |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA |
Application Notes | Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S 6P protein at 4°C overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS containing 0.05% DPBS-T for 1 h. Antibodies were diluted to 10 µg/mL and titrated two-fold 23 times in DPBS-T and added to the wells, followed by an incubation for 1 h at room temperature. After washing with DPBS-T, a goat anti-human IgG secondary antibody conjugated with horseradish peroxidase was added and incubated for one hour. Plates were then washed with DPBS-T and TMB substrate was added to each well. Reactions were quenched with 1 M hydrochloric acid and absorbance was measured at 450 nm using a spectrophotometer. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | SARS-CoV-2 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |